前列地尔联合川芎嗪治疗早期糖尿病肾病的疗效观察

目的:观察前列地尔(凯时)联合川芎嗪注射液(川青)治疗糖尿病肾病的临床疗效,探讨其降低尿蛋白,减轻肾损害的机制.方法:收集早期2型糖尿病患者120例,随机分成川芎嗪组(40例)、前列地尔组(40例)和联合治疗组(40例).全部病例进行临床观察2周,分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿蛋白定量治疗前后的变化.结果:治疗2周后,联合治疗组降低24 h尿蛋白定量的作用优于川芎嗪组和前列地尔组差异有统计学意义(P＜0.05).前列地尔组和川芎嗪组比较,差异有统计学意义(P＜0.05).结论:静脉应用前列地尔联合川芎嗪注射液能够降低糖尿病肾病患者尿蛋白,延缓糖尿病肾病的进展,值得临床推广.

The Effect of Ligustrazine and Alprostadil on the Early Diabetic Nephropathy

Objective: Ligustrazine and Alprostadil treatment of the early diabetic nephropathy.Methods: 120 patients with early type 2 diabetes of hospitalization were collected and randomly divided into 3 groups: Ligustrazine group(40 cases),Alprostadil group(40 cases),combined therapeutic group(40 cases).All cases were observed for 2 weeks.The changes of serum creatinine(Cr),blood urea nitrogen(BUN),24 hour urinary albumin before and after the treatment were compared.Results: After treatment for 2 weeks,the treatment of combined therapeutic group in decreasing 24 h urinary albumin was better than Ligustrazine group and Alprostadil group,the differences were significant(P<0.05).The differences between Ligustrazine group and Alprostadil group were significant(P<0.05).Conclusion: The treatment of Alprostadil combined with Irbesartan in early diabetic nephropathy is an effective way.Intravenous ligustrazine and alprostadil can delay the progression of diabetic nephropathy.It would be valuable to widespread popularization.